P. Hillmen, “The role of alemtuzumab in the treatment of chronic lymphocytic leukemia (CLL) and the achievement of minimal residual disease negativity in relapsed/refractory CLL”, Hematol Meeting Rep, vol. 1, no. 2, May 2009.